NEW YORK (GenomeWeb News) – Affymetrix said this week that the J. Craig Venter Institute has launched Affy's FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella. The new array is being made freely available to researchers from the National Institute of Allergy and Infectious Diseases-supported Pathogen Functional Genomics Resource Center.
Celera said this week that data is being presented at the 13th World Conference on Lung Cancer as part of the International Association for the Study of Lung Cancer in San Francisco showing that the firm's nine-biomarker immunoassay can detect lung cancer with 92 percent sensitivity and 93 percent specificity. The firm said that the panel also accurately distinguished malignant cases from benign lung disease.
The validation study was conducted in collaboration with scientists at NYU Langone Medical Center. Celera said that it confirms the performance of a nine-biomarker panel previously presented at the 100th Annual American Association for Cancer Research Conference in April 2009.
In addition, the authors of the study reported "high performance" of a six-marker panel derived from the nine-marker panel, which distinguished malignant cases with 92 percent sensitivity at 88 percent specificity. Celera said that it will continue to evaluate the clinical utility of both panels in an effort to determine which panel would offer optimal performance in a broad clinical setting.
Coral Springs, Fla.-based CyGene said this week that it has launched the first predictive DNA tests into the Russian market. The firm said that it had launched its predictive genetic products through its exclusive licensee, CyGene Russia.